跳至主要内容
临床试验/NCT03032835
NCT03032835招募中不适用

Partners Calciphylaxis Biobank and Patient Registry

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2017年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
300
试验地点
2
主要终点
Number of patients with improvement in calciphylaxis skin lesions

研究概览

简要总结

Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles.

There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis.

The Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.

详细描述

Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles.

There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis.

The Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.

This repository is working in collaboration with the Partners Biobank as they will still be receiving samples from the PCB and storing them and distributing them according to their own procedures.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female ≥18 years old
  • Skin lesions consistent with calciphylaxis diagnosis as determined by the treating clinician
  • Informed of the investigational nature of the study and sign written Informed consent OR are eligible for surrogate consent process based on impaired decision making

排除标准

  • Patients <18 years of age

研究组 & 干预措施

Study participants

No intervention

结局指标

主要结局

Number of patients with improvement in calciphylaxis skin lesions

时间窗: 6 months

Skin lesions will be assessed by investigators at baseline (entry into study) and at 6 months to determine whether there is improvement. The investigators will determine clinical, laboratory and genetic predictors of this outcome in calciphylaxis patients.

次要结局

  • Number of patients with >30% improvement in pain severity(4weeks)
  • Time to death in patients with calciphylaxis(Up to 5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sagar U. Nigwekar, MD, MMSc

Assistant in Medicine

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验